Samsung Bioepis applies for approval to sell Remicade biosimilar in U.S.
May 23, 2016 at 16:00 PM EDT
SEOUL, May 24 (Reuters) - South Korean biosimilars maker Samsung Bioepis Co Ltd said on Tuesday it has applied to the U.S. Food and Drug Administration (FDA) for approval to sell its version of blockbuster drug Remicade in the world's biggest healthcare market.
